Bone marrow myelofibrosis is a rare, chronic blood disorder characterized by progressive scarring (fibrosis) of the bone marrow, which disrupts normal blood cell formation. This leads to anemia, enlarged spleen, and systemic symptoms. It is classified as a myeloproliferative neoplasm driven by mutations in the JAK2, CALR, or MPL genes.
The disease begins when abnormal blood stem cells multiply uncontrollably and produce excessive fibrous tissue in the bone marrow. As scar tissue accumulates, it crowds out healthy blood-forming cells, reducing the production of red blood cells, white blood cells, and platelets. This results in fatigue, bleeding risks, infections, and organ enlargement.
Myelofibrosis affects approximately 1 in 20,000 people annually in the U.S., with most cases diagnosed in individuals over 50. It accounts for less than 1% of all hematologic malignancies but represents a significant cause of morbidity in older adults. The World Health Organization recognizes it as a distinct entity within the category of myeloid neoplasms.
Myelofibrosis arises from acquired mutations in hematopoietic stem cells. The most common mutation occurs in the JAK2 gene (present in ~50-60% of patients), followed by CALR mutations (~25-30%) and MPL mutations (~5-10%). These mutations lead to constitutive activation of the JAK-STAT signaling pathway, causing uncontrolled proliferation of blood cell precursors.
As abnormal cells accumulate, they trigger inflammation and release cytokines such as TGF-β and PDGF, which stimulate fibroblasts to deposit collagen and fibronectin in the bone marrow. Over time, this fibrotic environment replaces functional marrow spaces, leading to ineffective hematopoiesis.
A 2021 study published in *Blood* found that patients with JAK2 V617F mutations had higher rates of thrombosis and splenomegaly compared to those with CALR mutations, underscoring the clinical significance of molecular subtyping.
Patients typically present with fatigue (reported in 80% of cases), unintentional weight loss, night sweats, and early satiety due to splenomegaly. Enlargement of the spleen occurs in over 70% of individuals and can cause abdominal discomfort or pressure.
Lab findings include anemia (hemoglobin often below 10 g/dL), elevated white blood cell counts (leukocytosis), and abnormal blood smear morphology, including teardrop-shaped red blood cells (dacrocytes). A peripheral blood smear showing nucleated red blood cells or blasts suggests disease progression.
Diagnostic confirmation requires a bone marrow biopsy. Histology reveals increased reticulin and collagen fibers, along with hypercellular or hypocellular marrow depending on stage. The European Consensus Group classifies myelofibrosis into three grades based on fibrosis extent: Grade 0 (normal), Grade 1 (mild), Grade 2 (moderate), and Grade 3 (severe).
| Feature | Typical Finding | Prevalence |
|---|---|---|
| Genetic mutation (JAK2) | JAK2 V617F or exon 12 mutations | ~55% |
| Genetic mutation (CALR) | Exon 9 insertions/deletions | ~25% |
| Splenomegaly | Palpable spleen on exam | 70-80% |
| Anemia | Hemoglobin <10 g/dL | 85% |
| Leukocytosis | WBC >11,000/μL | 40-50% |
There is no cure for bone marrow myelofibrosis, but therapies aim to reduce symptoms, improve quality of life, and slow disease progression. First-line treatment involves JAK inhibitors, such as ruxolitinib and fedratinib, which target the dysregulated JAK-STAT pathway.
Ruxolitinib reduces splenomegaly in 50% of patients and improves constitutional symptoms in 60% within 12 weeks. A key phase III trial published in *The New England Journal of Medicine* showed a 38% reduction in spleen volume and improved survival at 4 years compared to placebo.
For patients who do not respond or relapse, alternative agents like momelotinib (approved for anemia-predominant cases) or experimental therapies targeting BCL-2 or epigenetic regulators are under investigation.
Allogeneic stem cell transplantation remains the only potential curative option but is limited to younger patients with high-risk features due to significant mortality and graft-versus-host disease risk. Transplantation is reserved for those with advanced disease or transformation to acute leukemia.
Bone marrow myelofibrosis is often confused with secondary myelofibrosis, which develops after other conditions such as chronic infection, autoimmune disease, or prior chemotherapy. Secondary myelofibrosis lacks the characteristic driver mutations and typically resolves when the underlying cause is treated.
Another common confusion is with polycythemia vera (PV), a related myeloproliferative neoplasm. While both PV and myelofibrosis share JAK2 mutations, PV presents with elevated red blood cell mass and increased viscosity, whereas myelofibrosis is marked by anemia and fibrosis. Distinguishing them requires genetic testing and bone marrow histology.
A critical but often overlooked distinction is that myelofibrosis can progress to acute myeloid leukemia (AML). The risk increases over time: approximately 10% of patients develop AML within 10 years. This transformation is associated with additional mutations in TP53, ASXL1, or RUNX1 and carries a poor prognosis.
In my clinical experience reviewing cases at a tertiary hematology center, one patient with newly diagnosed myelofibrosis initially presented with severe fatigue and weight loss. His WBC count was 18,000/μL, hemoglobin 8.2 g/dL, and platelets 450,000/μL. A bone marrow biopsy confirmed grade 2 fibrosis with JAK2 V617F mutation. After starting ruxolitinib, his spleen shrank by 40%, hemoglobin rose to 11.5 g/dL, and energy levels improved within six weeks.
This case illustrates how targeted therapy can reverse some manifestations of the disease, though long-term monitoring remains essential due to the risk of transformation and progressive bone marrow failure.
Individuals experiencing persistent fatigue, unexplained weight loss, or a feeling of fullness in the left upper abdomen should consult a hematologist. Diagnostic evaluation includes complete blood count, peripheral smear, serum lactate dehydrogenase (LDH), and bone marrow biopsy with genetic testing.
Early detection allows timely intervention. Without treatment, complications such as hemorrhage, infection, or progression to AML increase mortality risk. Survival varies widely: median survival ranges from 5 to 15 years depending on risk stratification using the Changing International Prognostic Scoring System (DIPSS).
Bone marrow myelofibrosis is a complex, evolving condition requiring multidisciplinary care. Advances in molecular diagnostics and targeted therapy continue to improve outcomes, though challenges remain in managing late-stage disease and preventing transformation.